Literature DB >> 25313237

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Patrick Y Wen1, Timothy F Cloughesy1, Benjamin M Ellingson1, David A Reardon1, Howard A Fine1, Lauren Abrey1, Karla Ballman1, Martin Bendszuz1, Jan Buckner1, Susan M Chang1, Michael D Prados1, Whitney B Pope1, Alma Gregory Sorensen1, Martin van den Bent1, Wai-Kwan Alfred Yung1.   

Abstract

On January 30, 2014, a workshop was held on neuroimaging endpoints in high-grade glioma. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, Accelerate Brain Cancer Cure, and the Musella Foundation for Research and Information, and conducted in collaboration with the Food and Drug Administration. The workshop included neuro-oncologists, neuroradiologists, radiation oncologists, neurosurgeons, biostatisticians, patient advocates, and representatives from industry, clinical research organizations, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to improve the Response Assessment in Neuro-Oncology (RANO) criteria and standardize neuroimaging parameters.
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  RANO; brain tumor; endpoints; neuroimaging; workshop

Mesh:

Year:  2014        PMID: 25313237      PMCID: PMC4195530          DOI: 10.1093/neuonc/nou226

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  60 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Ramon F Barajas; Jamie S Chang; Mark R Segal; Andrew T Parsa; Michael W McDermott; Mitchel S Berger; Soonmee Cha
Journal:  Radiology       Date:  2009-09-29       Impact factor: 11.105

3.  The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors.

Authors:  Armin Michael Nagel; Michael Bock; Christian Hartmann; Lars Gerigk; Jan-Oliver Neumann; Marc-André Weber; Martin Bendszus; Alexander Radbruch; Wolfgang Wick; Heinz-Peter Schlemmer; Wolfhard Semmler; Armin Biller
Journal:  Invest Radiol       Date:  2011-09       Impact factor: 6.016

4.  An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.

Authors:  Anca-Ligia Grosu; Sabrina T Astner; Eva Riedel; Carsten Nieder; Nicole Wiedenmann; Felix Heinemann; Markus Schwaiger; Michael Molls; Hans-Jürgen Wester; Wolfgang A Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-11       Impact factor: 7.038

5.  Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

Authors:  John F de Groot; Kathleen R Lamborn; Susan M Chang; Mark R Gilbert; Timothy F Cloughesy; Kenneth Aldape; Jun Yao; Edward F Jackson; Frank Lieberman; H Ian Robins; Minesh P Mehta; Andrew B Lassman; Lisa M Deangelis; W K Alfred Yung; Alice Chen; Michael D Prados; Patrick Y Wen
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

6.  Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

Authors:  Benjamin M Ellingson; Mark G Malkin; Scott D Rand; Jennifer M Connelly; Carolyn Quinsey; Pete S LaViolette; Devyani P Bedekar; Kathleen M Schmainda
Journal:  J Magn Reson Imaging       Date:  2010-03       Impact factor: 4.813

7.  Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Authors:  Fabio M Iwamoto; Kathleen R Lamborn; H Ian Robins; Minesh P Mehta; Susan M Chang; Nicholas A Butowski; Lisa M Deangelis; Lauren E Abrey; Wei-Ting Zhang; Michael D Prados; Howard A Fine
Journal:  Neuro Oncol       Date:  2010-03-03       Impact factor: 12.300

8.  Magnetic resonance imaging of the Amine-Proton EXchange (APEX) dependent contrast.

Authors:  Tao Jin; Ping Wang; Xiaopeng Zong; Seong-Gi Kim
Journal:  Neuroimage       Date:  2011-08-16       Impact factor: 6.556

9.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

View more
  24 in total

Review 1.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

2.  Brain tumor clinical trials imaging: a (well-standardized) picture is worth a thousand words.

Authors:  Joohee Sul; Daniel M Krainak
Journal:  Neuro Oncol       Date:  2015-09       Impact factor: 12.300

Review 3.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

4.  Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI.

Authors:  Benjamin M Ellingson; Albert Lai; Huytram N Nguyen; Phioanh L Nghiemphu; Whitney B Pope; Timothy F Cloughesy
Journal:  Clin Cancer Res       Date:  2015-04-21       Impact factor: 12.531

Review 5.  Creating clinical trial designs that incorporate clinical outcome assessments.

Authors:  Mark R Gilbert; Lawrence Rubinstein; Glenn Lesser
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

6.  How treatment monitoring is influencing treatment decisions in glioblastomas.

Authors:  Martha R Neagu; Raymond Y Huang; David A Reardon; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 7.  Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.

Authors:  Dewen Yang
Journal:  Neurooncol Pract       Date:  2015-07-12

Review 8.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).

Authors:  Jennifer L Helfer; Patrick Y Wen; Jaishri Blakeley; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

9.  Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling error.

Authors:  Brendan J McCullough; Valerie Ader; Brian Aguedan; Xu Feng; Daniel Susanto; Tara L Benkers; John W Henson; Marc Mayberg; Charles S Cobbs; Ryder P Gwinn; Stephen J Monteith; David W Newell; Johnny Delashaw; Sarah J Fouke; Steven Rostad; Bart P Keogh
Journal:  J Neurooncol       Date:  2017-11-02       Impact factor: 4.130

Review 10.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.